冠状动脉生物可吸收支架的盲法结局与心绞痛评估:ABSORB IV随机试验的30天和1年结果
ABSORB IV是一项在5个国家147家医院开展的活性对照、盲法、多中心随机试验,纳入2604例稳定冠心病或急性冠脉综合征患者,1:1随机接受聚合物依维莫司洗脱生物可吸收支架(BVS,n=1296)或钴铬依维莫司洗脱支架(EES,n=1308)。主要终点30天靶病变失败率BVS组5.0% vs EES组3.7%,差异1.3%(单侧非劣效P=0.0244);1年靶病变失败率BVS组7.8% vs EES组6.4%,差异1.4%(单侧非劣效P=0.0006)。1年心绞痛发生率BVS组20.3% vs EES组20.5%,差异-0.3%(95%CI -3.4%至2.9%),非劣效P=0.0008,优效P=0.8603。1年内器械血栓BVS组0.7% vs EES组0.3%(P=0.1586)。
要点
- 30天靶病变失败率BVS组5.0% vs EES组3.7%,差异1.3%,单侧非劣效P=0.0244,达到非劣效。
- 1年靶病变失败率BVS组7.8% vs EES组6.4%,差异1.4%,单侧非劣效P=0.0006,达到非劣效。
- 1年心绞痛发生率BVS组20.3% vs EES组20.5%,差异-0.3%(95%CI -3.4%至2.9%),非劣效P=0.0008,优效P=0.8603。
- 1年内器械血栓发生率BVS组0.7% vs EES组0.3%,P=0.1586。
- 生物标志物阳性的急性冠脉综合征患者占24%(622/2602),极细小血管病变占3%(78/2893)。
适用人群与场景
- 年龄18岁及以上、稳定冠心病或急性冠脉综合征的患者。
- 来自5个国家(美国、德国、澳大利亚、新加坡、加拿大)147家医院。
- 生物标志物阳性的急性冠脉综合征患者622例(24%,622/2602)。
- 按血管造影核心实验室分析,极细小血管病变78处(3%,78/2893)。
处置流程与药物剂量
- 聚合物依维莫司洗脱生物可吸收支架(Absorb;Abbott Vascular,Santa Clara,CA,USA)采用优化植入技术。
- 对照为钴铬依维莫司洗脱支架(EES;Xience;Abbott Vascular,Santa Clara,CA,USA)。
- 随机化按糖尿病状态、是否符合既往ABSORB III试验入组条件及研究中心分层。
- 患者与临床评估者均对随机分组设盲。
研究设计与关键结果
- 研究类型:活性对照、盲法、多中心随机试验;纳入2604例患者,BVS组1296例,EES组1308例。
- 30天靶病变失败(心源性死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建)BVS组64例(5.0%) vs EES组48例(3.7%),差异1.3%,单侧非劣效P=0.0244。
- 1年靶病变失败BVS组98例(7.8%) vs EES组82例(6.4%),差异1.4%,单侧非劣效P=0.0006。
- 1年心绞痛(中心事件委员会裁定)BVS组270例(20.3%) vs EES组274例(20.5%),差异-0.3%(95%CI -3.4%至2.9%),单侧非劣效P=0.0008,双侧优效P=0.8603。
- 1年内器械血栓BVS组9例(0.7%) vs EES组4例(0.3%),P=0.1586。
- 随访数据:30天时BVS组1288例、EES组1303例;1年时BVS组1254例、EES组1272例。
证据类型、等级与局限
- 证据类型:随机对照试验(ABSORB IV)。
对床旁实践的改变
- 在优化植入技术和扩大的人群(包括生物标志物阳性急性冠脉综合征患者)中,聚合物BVS的30天和1年靶病变失败率及心绞痛发生率不劣于金属DES。
- 1年内器械血栓发生率BVS组0.7% vs EES组0.3%,P=0.1586,两组间无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Previous studies showed more adverse events with coronary bioresorbable vascular scaffolds (BVS) than with metallic drug-eluting stents (DES), although in one randomised trial angina was reduced with BVS. However, these early studies were unmasked, lesions smaller than intended for the scaffold were frequently enrolled, implantation technique was suboptimal, and patients with myocardial infarction, in whom BVS might be well suited, were excluded.
METHODS: In the active-controlled, blinded, multicentre, randomised ABSORB IV trial, patients with stable coronary artery disease or acute coronary syndromes aged 18 years or older were recruited from 147 hospitals in five countries (the USA, Germany, Australia, Singapore, and Canada). Enrolled patients were randomly assigned (1:1) to receive polymeric everolimus-eluting BVS (Absorb; Abbott Vascular, Santa Clara, CA, USA) with optimised implantation technique or cobalt-chromium everolimus-eluting stents (EES; Xience; Abbott Vascular, Santa Clara, CA, USA). Randomisation was stratified by diabetic status, whether patients would have been eligible for enrolment in the previous ABSORB III trial, and site. Patients and clinical assessors were masked to randomisation. The primary endpoint was target lesion failure (cardiac death, target vessel myocardial infarction, or ischaemia-driven target lesion revascularisation) at 30 days, tested for non-inferiority with a 2·9% margin for the risk difference. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT02173379, and is closed to accrual.
FINDINGS: Between Aug 15, 2014, and March 31, 2017, we screened 18 722 patients for eligibility, 2604 of whom were enrolled. 1296 patients were assigned to BVS, and 1308 patients were assigned to EES. Follow-up data at 30 days and 1 year, respectively, were available for 1288 and 1254 patients with BVS and for 1303 and 1272 patients with EES. Biomarker-positive acute coronary syndromes were present in 622 (24%) of 2602 patients, and, by angiographic core laboratory analysis, 78 (3%) of 2893 of lesions were in very small vessels. Target lesion failure at 30 days occurred in 64 (5·0%) patients assigned to BVS and 48 (3·7%) patients assigned to EES (difference 1·3%, upper 97·5% confidence limit 2·89; one-sided pnon-inferiority=0·0244). Target lesion failure at 1 year occurred in 98 (7·8%) patients assigned to BVS and 82 (6·4%) patients assigned to EES (difference 1·4%, upper 97·5% confidence limit 3·4; one-sided pnon-inferiority=0·0006). Angina, adjudicated by a central events committee at 1 year, occurred in 270 (20·3%) patients assigned to BVS and 274 (20·5%) patients assigned to EES (difference -0·3%, 95% CI -3·4% to 2·9%; one-sided pnon-inferiority=0·0008; two-sided psuperiority=0·8603). Device thrombosis within 1 year occurred in nine (0·7%) patients assigned to BVS and four (0·3%) patients assigned to EES (p=0·1586).
INTERPRETATION: Polymeric BVS implanted with optimised technique in an expanded patient population resulted in non-inferior 30-day and 1-year rates of target lesion failure and angina compared with metallic DES.
FUNDING: Abbott Vascular.
参考来源
- Stone GW, Ellis SG, Gori T, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet. 2018. PMID: 30266412. doi:10.1016/S0140-6736(18)32283-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。